Although current recommendations suggest that a combination of a protease inhibitor plus two nucleosides represents standard of care for HIV infection, as many as 50% of patients will relapse on such a regimen. This study will attempt to determine the best next treatment for patients who fail the most commonly used triple regimen, nelfinavir plus two nucleosides.
Showing the most recent 10 out of 497 publications